Statistical modeling and verification for the synthesis of median survival time in multilevel meta-analysis of survival data
暂无分享,去创建一个
Jia He | Shurong Zou | Jiajie Zang | Jinfang Xu | Chun Xiang | S. Zou | J. Zang | Jin-fang Xu | Jia He | Chun Xiang
[1] M. Parmar,et al. Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.
[2] M. S. Patel,et al. An introduction to meta-analysis. , 1989, Health Policy.
[3] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[5] W. Evans. Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer. , 2004, Cancer treatment reviews.
[6] Bruce E. Johnson,et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2010 .
[7] R M Turner,et al. Multilevel models for meta-analysis, and their application to absolute risk differences , 2001, Statistical methods in medical research.
[8] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Robinson,et al. Modelling survival data in medical research, second edition , 2004 .
[10] D. Altman,et al. Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.
[11] M. Cheung. Computing effect sizes for meta‐analysis , 2015 .
[12] W. D. Ray. 4. Modelling Survival Data in Medical Research , 1995 .
[13] Multi-level model synthesis of median survival time in meta-analysis. , 2015, Epidemiology.
[14] J. Zang,et al. Synthesis of median survival time in meta-analysis. , 2013, Epidemiology.
[15] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Giaccone,et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Mark C Simmonds,et al. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice , 2005, Clinical trials.
[18] J. Milanowski,et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[20] S. Sharp,et al. Explaining heterogeneity in meta-analysis: a comparison of methods. , 1999 .
[21] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[22] Richard D Riley,et al. Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. , 2007, Journal of clinical epidemiology.
[23] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[24] Stefan Michiels,et al. Meta-analysis when only the median survival times are known: A comparison with individual patient data results , 2005, International Journal of Technology Assessment in Health Care.
[25] R. Singh,et al. Survival analysis in clinical trials: Basics and must know areas , 2011, Perspectives in clinical research.
[26] T. Mok,et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Theo Stijnen,et al. Meta‐analysis of summary survival curve data , 2008, Statistics in medicine.
[28] L. Hedges,et al. Introduction to Meta‐Analysis , 2009, International Coaching Psychology Review.
[29] B. Milleron,et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. , 2010 .
[30] J. Pignon,et al. Meta-analyses of randomised clinical trials in oncology. , 2001, The Lancet. Oncology.
[31] G. Giaccone,et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.
[32] V. Torri,et al. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). , 2010 .
[33] C D Naylor,et al. Meta-analysis of controlled clinical trials. , 1989, The Journal of rheumatology.